Apellis Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-4.48; its P/E ratio is -11.57; Apellis Pharmaceuticals is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-0.46. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 110.40M	$ 89.64M	$ 44.85M	$ 22.66M	$ 22.06M
Gross Profit	$ 110.40M	$ 94.97M	$ 44.85M	$ 19.74M	$ 20.68M
EBIT	$ -139.11M	$ -120.95M	$ -169.97M	$ -159.72M	$ -182.92M
EBITDA	$ -138.57M	$ -120.45M	$ -169.47M	$ -159.30M	$ -182.56M
Net Income Common Stockholders	$ -88.11M	$ -122.04M	$ -177.78M	$ -165.99M	$ -191.27M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 452.40M	$ 617.38M	$ 766.38M	$ 551.80M	$ 708.55M
Total Assets	$ 818.22M	$ 915.61M	$ 978.87M	$ 760.22M	$ 872.89M
Total Debt	$ 109.58M	$ 110.80M	$ 111.87M	$ 112.71M	$ 113.37M
Net Debt	$ -342.82M	$ -506.58M	$ -654.50M	$ -439.09M	$ -595.18M
Total Liabilities	$ 585.95M	$ 570.17M	$ 566.75M	$ 590.35M	$ 565.48M
Stockholders Equity	$ 232.27M	$ 354.08M	$ 412.12M	$ 169.87M	$ 307.42M
Cash Flow	-
Free Cash Flow	$ -169.13M	$ -150.53M	$ -177.88M	$ -141.59M	$ -154.61M
Operating Cash Flow	$ -169.09M	$ -150.16M	$ -177.62M	$ -140.74M	$ -154.42M
Investing Cash Flow	$ -47.00K	$ -372.00K	$ -259.00K	$ 124.13M	$ 124.78M
Financing Cash Flow	$ 5.75M	$ 1.56M	$ 391.11M	$ -15.95M	$ 9.64M

Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History

Income Statement >

Apellis Pharmaceuticals Debt to Assets

Balance Sheet >

Apellis Pharmaceuticals Cash Flow

Cash Flow >

Apellis Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing